teprotumumab

Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Fierce Pharma
Fri, 01/3/20 - 11:03 pm
FDA
migraines
cholesterol
Epizyme
tazemetostat
Esperion
bempedoic acid
teprotumumab
Horizon Therapeutics
Biohaven
rimegepant
FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug
Endpoints
Fri, 12/13/19 - 09:32 pm
FDA
advisory panels
Horizon Therapeutics
thyroid eye disease
teprotumumab
FDA in-house review spotlights an issue with one of Horizon's endpoints but notes efficacy for lead drug
Endpoints
Thu, 12/12/19 - 11:01 am
FDA
Horizon Pharma
clinical trials
teprotumumab
thyroid eye disease
Horizon looks for a new growth driver
EP Vantage
Mon, 10/28/19 - 10:33 am
Horizon
Graves' disease
teprotumumab
Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease
Pharmaceutical Business Review
Tue, 09/10/19 - 09:41 am
Horizon Therapeutics
FDA
teprotumumab
thyroid eye disease
priority review
Horizon Pharma’s Thyroid Eye Disease Treatment Could Become a Blockbuster, Analyst Predicts
BioSpace
Mon, 04/29/19 - 09:37 pm
Horizon Pharma
thyroid eye disease
teprotumumab
After thyroid eye drug scores in PhIII test, Horizon Pharma readies marketing application
Endpoints
Fri, 03/1/19 - 09:29 am
thyroid eye disease
Horizon Pharma
teprotumumab
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Fierce Biotech
Mon, 05/8/17 - 10:07 pm
Horizon Pharma
River Vision
eye health
teprotumumab
thyroid eye disease